Clinical Trial Update: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding a repurposed drug to the combination of lenvatinib plus pembrolizumab in advanced endometrial cancer. The study is currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Evergreen Therapeutics, Inc. | Conditions: Advanced Endometrial Cancer | Phase 3 | Status: NOT_YET_RECRUITING